European respiratory update: Update on diffuse parenchymal lung disease

European Respiratory Review

Volumn 19, Issue 116, 2010, Pages 97-108

  Harari, S ^a   Caminati, A ^a  

^a San Giuseppe Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMBRISENTAN; AZATHIOPRINE; BOSENTAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXYCYCLINE; ENDOTHELIN RECEPTOR ANTAGONIST; EVEROLIMUS; GAMMA INTERFERON; MACITENTAN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIRFENIDONE; PLACEBO; PREDNISONE; RAPAMYCIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ALLERGIC PNEUMONITIS; CLINICAL FEATURE; COMORBIDITY; CONNECTIVE TISSUE DISEASE; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FIBROSING ALVEOLITIS; HISTOPATHOLOGY; HUMAN; INTERSTITIAL PNEUMONIA; LUNG DISEASE; LUNG FIBROSIS; LUNG PARENCHYMA; LYMPHANGIOLEIOMYOMATOSIS; MORTALITY; PATHOGENESIS; PROGNOSIS; PULMONARY HYPERTENSION; RADIODIAGNOSIS; REVIEW; UNSPECIFIED SIDE EFFECT; LUNG TUMOR; PNEUMONIA; PREVALENCE;

HUMANS; LUNG NEOPLASMS; LYMPHANGIOLEIOMYOMATOSIS; PNEUMONIA; PREVALENCE; PROGNOSIS; PULMONARY FIBROSIS;

EID: 77953187384     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.00002510     Document Type: Review

References (124)

1. Olson AL, Swigris JJ, Lezotte DC, et al. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med 2007; 176: 277-284.
2. Panos RJ, Mortenson RL, Niccoli SA, et al. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 1990; 88: 396-404.
3. Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005; 142: 963-967.
4. Daniels CE, Yi ES, Ryu JH. Autopsy findings in 42 consecutive patients with idiopathic pulmonary fibrosis. Eur Respir J 2008; 32: 170-174.
5. Le Jeune I, Gribbin J, West J, et al. The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir Med 2007; 101: 2534-2540.
6. Vancheri C, Failla M, Crimi N, et al. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 2010; 35: 496-504.
7. Kizer JR, Zisman DA, Blumenthal NP, et al. Association between pulmonary fibrosis and coronary artery disease. Arch Intern Med 2004; 164: 551-556.
8. Hubbard RB, Smith C, Le Jeune I, et al. The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am J Respir Crit Care Med 2008; 178: 1257-1261.
9. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007; 16: 636-643.
10. Sumikawa H, Johkoh T, Colby TV, et al. Computed tomography findings in pathological usual interstitial pneumonia: relation- ship to survival. Am J Respir Crit Care Med 2008; 177: 433-439.
11. Flaherty KR. High-resolution computed tomography and the many faces of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177: 367-368.
12. Jegal Y, Kim DS, Shim TS, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005; 171: 639-644.
13. Flaherty KR, Andrei A-C, Murray S, et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six minute hallwalk. Am J Resp Crit Care Med 2006; 174: 803-809.
14. King TE Jr, Safrin S, Starko KM, et al. Analyses of efficacy end points in a controlled trial of interferon-cb for idiopathic pulmonary fibrosis. Chest 2005; 127: 171-177.
15. Lederer DJ, Arcasoy SM, Wilt JS, et al. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174: 659-664.
16. Caminati A, Bianchi A, Cassandro R, et al. Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Respir Med 2009; 103: 117-123.
17. Fell CD, Liu LX, Motika C, et al. The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Resp Crit Care Med 2009; 179: 402-407.
18. Ryu YJ, Chung MP, Han J, et al. Bronchoalveolar lavage in fibrotic idiopathic interstitial pneumonias. Respir Med 2007; 101: 655-660.
19. Kinder BW, Brown KK, Schwarz MI, et al. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest 2008; 133: 226-232.
20. Ohshimo S, Bonella F, Cui A, et al. Significance of bronchoalveo- lar lavage for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179: 1043-1047.
21. Kinder BW, Wells AU. The art and science of diagnosing interstitial lung diseases. Am J Respir Crit Care Med 2009; 179: 974-975.
22. Phelps DS, Umstead TM, Mejia M, et al. Increased surfactant protein-A levels in patients with newly diagnosed idiopathic pulmonary fibrosis. Chest 2004; 125: 617-625.
23. Kinder BW, Brown KK, McCormack FX, et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest 2009; 135: 1557-1563.
24. Agarwal R, Jindal SK. Acute exacerbation of idiopathic pulmon- ary fibrosis: a systematic review. Eur J Intern Med 2008; 19: 227-235.
25. Enomoto N, Suda T, Uto T, et al. Possible therapeutic effect of direct haemoperfusion with a polymyxin B immobilized fibre column (PMX-DHP) on pulmonary oxygenation in acute exacerbations of interstitial pneumonia. Respirology 2008; 13: 452-460.
26. Parambil JG, Myers JL, Ryu JH. Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. Chest 2005; 128: 3310-3315.
27. Kim DS, Park JH, Park BK, et al. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J 2006; 27: 143-150.
28. Ambrosini V, Cancellieri A, Chilosi M, et al. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur Respir J 2003; 22: 821-826.
29. Churg A, Muller NL, Silva IS, et al. Acute exacerbation (acute lung injury of unknown cause) in UIP and other forms of fibrotic interstitial pneumonias. Am J Surg Pathol 2007; 31: 277-284.
30. Akira M, Kozuka T, Yamamoto S, et al. Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 178: 372-378.
31. Hyzy R, Huang S, Myers J, et al. Acute exacerbation of idiopathic pulmonary fibrosis. Chest 2007; 132: 1652-1658.
32. Vannella KM, Moore BB. Viruses as co-factors for the initiation or exacerbation of lung fibrosis. Fibrogenesis Tissue Repair 2008; 1: 2.
33. Tomioka H, Sakurai T, Hashimoto K, et al. Acute exacerbation of idiopathic pulmonary fibrosis: role of Chlamydophila pneumonia infection. Respirology 2007; 12: 700-706.
34. Konishi K, Gipson KF, Lindell KO, et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 180: 167-175.
35. Selman M, Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thorac Soc 2006; 3: 364-372.
36. King TE Jr, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177: 75-81.
37. King TE Jr, Albera C, Bradford WZ, et al. Effect of interferon c-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009; 374: 222-228.
38. Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo- controlled trial. Am J Respir Crit Care Med 2008; 178: 948-955.
39. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2229-2242.
40. Jackson RM, Fell CD. Etanercept for idiopathic pulmonary fibrosis. Lessons on clinical trial design. Am J Respir Crit Care Med 2008; 178: 889-891.
41. Daniels CE, Lasky JA, Limper AH, et al. Imatinib treatment for idiopathic pulmonary fibrosis. Randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010; 181: 604-610.
42. Varney VA, Parnell HM, Salisbury DT, et al. A double blind randomised placebo controlled pilot study of oral cotrimoxazole in advanced fibrotic lung disease. Pulm Pharmacol Ther 2008; 21: 178-187.
43. Nishiyama O, Kondoh Y, Kimura T, et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology 2008; 13: 394-399.
44. Holland AE, Hill CJ, Conron M, et al. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax 2008; 63: 549-554.
45. Spruit MA, Jansenn DJA, Franssen FME, et al. Rehabilitation and palliative care in lung fibrosis. Respirology 2009; 14: 781-787.
46. Noble P, Albera C, Bradford P, et al. The CAPACITY (CAP) trials: randomized, double-blind, placebo-controlled, phase III trials of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF). Am J Respir Crit Care Med 2009; 179: A1129.
47. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis a phase III clinical trial in Japan. Eur Respir J 2010; 35: 821-829.
48. Harari S, Caminati A. IPF: new insight on pathogenesis and treatment. Allergy 2010; [Epub ahead of print DOI: 10.1111/ j.1398-9995.2009.02305.x].
49. Verma S, Slutsky AS. Idiopathic pulmonary fibrosis: new insights. N Engl J Med 2007; 356: 1370-1372.
50. Steele MP, Speer MC, Loyd JE, et al. Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med 2005; 172: 1146-1152.
51. Armanios MY, Chen JJ, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007; 356: 1317-1326.
52. King TE Jr, du Bois RM. Elucidating the causes and examining the latest clinical findings in pulmonary fibrosis. Eur Respir Rev 2008; 17: 105-107.
53. Loyd JE. Gene expression profiling: can we identify the right target genes? Eur Respir Rev 2008; 17: 163-167.
54. Cronkhite JT, Xing C, Raghu G, et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 178: 729-737.
55. Alder JK, Chen JJ, Lancaster L, et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci USA 2008; 105: 13051-13056.
56. Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174: 810-816.
57. Lama VN, Smith L, Badri L, et al. Evidence for tissue-resident mesenchymal stem cells in human adult lung from studies of transplanted allografts. J Clin Invest 2007; 117: 989-996.
58. Summer R, Fitzsimmons K, Dwyer D, et al. Isolation of an adult mouse lung mesenchymal progenitor cell population. Am J Respir Cell Mol Biol 2007; 37: 152-159.
59. Martin J, Helm K, Ruegg P, et al. Adult lung side population cells have mesenchymal stem cell potential. Cytotherapy 2008; 10: 140-151.
60. Driscoll B, Buckley S, Bui KC, et al. Telomerase in alveolar epithelial development and repair. Am J Physiol Lung Cell Mol Physiol 2000; 279: L1191-L1198.
61. Blasco MA. Telomere length, stem cells and aging. Nat Chem Biol 2007; 3: 640-649.
62. Samper E, Fernandez P, Eguia R, et al. Long-term repopulating ability of telomerase-deficient murine hematopoietic stem cells. Blood 2002; 99: 2767-2775.
63. Thannickal VJ, Loyd JE. Idiopathic pulmonary fibrosis. A disorder of lung regeneration? Am J Respir Crit Care Med 2008; 178: 663-665.
64. Korfei M, Ruppert C, Mahavadi P, et al. Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 178: 838-846.
65. Willis BC, du Bois RM, Borok Z. Epithelial origin of myofibro- blasts during fibrosis in the lung. Proc Am Thorac Soc 2006; 3: 377-382.
66. Bellini A, Mattoli S. The role of the fibrocyte, a bone marrow- derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest 2007; 87: 858-870.
67. Moeller A, Gilpin SE, Ask K, et al. Circulating fibrocytes are an indicator for poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179: 588-594.
68. Moore BB. Fibrocytes as potential biomarkers in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179: 524-525.
69. Selman M, Pardo A, Kaminski N. Idiopathic pulmonary fibrosis: aberrant recapitulation of developmental programs? PLoS Med 2008; 5: e62.
70. Konigshoff M, Balsara N, Pfaff EM, et al. Functional Wnt signaling is increased in idiopathic pulmonary fibrosis. PLoS One 2008; 3: e2142.
71. Myllarniemi M, Lindholm P, Ryynanen MJ, et al. Gremlin- mediated decrease in bone morphogenetic protein signaling promotes pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177: 321-329.
72. Travis WD, Hunninghake G, King TE Jr, et al. Idiopathic non- specific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med 2008; 177: 1338-1347.
73. Kinder BW, Collard HR, Koth L, et al. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated EUROPEAN RESPIRATORY REVIEW connective tissue disease? Am J Respir Crit Care Med 2007; 176: 691-697.
74. Park IN, Jegal Y, Kim DS, et al. Clinical course and lung function change of idiopathic nonspecific interstitial pneumonia. Eur Respir J 2009; 33: 68-76.
75. Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia. Idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007; 175: 705-711.
76. Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis associated interstitial lung disease. Chest 2005; 127: 2019-2027.
77. Yoshinouchi T, Ohtsuki Y, Fujita J, et al. Nonspecific interstitial pneumonia pattern as pulmonary involvement of rheumatoid arthritis. Rheumatol Int 2005; 26: 121-125.
78. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010; 35: 1322-1328.
79. Tashkin DP, Elashoff R, Clements PJ, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007; 176: 1026-1034.
80. Wells AU, Latsi P, McCune WJ. Daily cyclophosphamide for scleroderma: are patients with the most to gain underrepre- sented in this trial? Am J Respir Crit Care Med 2007; 176: 952-953.
81. Zamora AC, Wolters PJ, Collard HR, et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 2008; 102: 150-155.
82. Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated inter- stitial lung disease. Chest 2008; 133: 455-460.
83. Berezne A, Ranque B, Valeyre D, et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease asso- ciated with systemic sclerosis: a retrospective multicenter open- label study. J Rhematol 2008; 35: 1064-1072.
84. Goh NS, Veeraraghavan S, Desai SR, et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis- associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum 2007; 56: 2005-2012.
85. Gilson M, Zerkak D, Wipff J, et al. Prognostic factors for lung function in systemic sclerosis: prospective study of 105 cases. Eur Respir J 2010; 35: 112-117.
86. Strange C, Bolster MB, Roth MD, et al. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 2008; 177: 91-98.
87. El-Zammar OA, Katzenstein AL. Pathological diagnosis of granulomatous lung disease: a review. Histopathology 2007; 50: 289-310.
88. Churg A, Muller NL, Flint J, et al. Chronic hypersensitivity pneumonitis. Am J Surg Pathol 2006; 30: 201-208.
89. Trahan S, Hanak V, Ryu JH, et al. Role of surgical lung biopsy in separating chronic hypersensitivity pneumonia from usual interstitial pneumonia/idiopathic pulmonary fibrosis. Analysis of 31 biopsies from 15 patients. Chest 2008; 134: 126-132.
90. Silva CI, Churg A, Muller NL. Hypersensitivity pneumonitis: spectrum of high-resolution CT and pathologic findings. AJR Am J Roentgenol 2007; 188: 334-344.
91. Hanak V, Golbin JM, Hartman TE, et al. High-resolution CT findings of parenchymal fibrosis correlate with prognosis in hypersensitivity pneumonitis. Chest 2008; 134: 133-138.
92. Silva CI, Muller NL, Lynch DA, et al. Chronic hypersensitivity pneumonitis: differentiation from idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia by using thin section CT. Radiology 2008; 246: 288-297.
93. Olson AL, Huie TJ, Groshong SD, et al. Acute exacerbations of fibrotic hypersensitivity pneumonitis: a case series. Chest 2008; 134: 844-850.
94. Johnson SR, Tattersfield AE. Decline in lung function in lymphangioleiomyomatosis: relation to menopause and pro- gesterone treatment. Am J Respir Crit Care Med 1999; 160: 628-633.
95. Taveira-Dasilva AM, Stylianou MP, Hedin CJ, et al. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest 2004; 126: 1867-1874.
96. Harari S, Cassandro R, Chiodini J, et al. Effect of a gonadotrophin- releasing hormone analogue on lung function in lymphangioleio- myomatosis. Chest 2008; 133: 448-454.
97. Lazor R, Valeyre D, Lacronique J, et al. The Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P). Low initial KCO predicts rapid FEV1 decline in pulmonary lymphangioleiomyomatosis. Respir Med 2004; 98: 536-541.
98. Taveira-DaSilva AM, Steagall WK, Rabel A, et al. Reversible airflow obstruction in lymphangioleiomyomatosis. Chest 2009; 136: 1596-1603.
99. Goncharova EA, Goncharov DA, Spaits M, et al. Abnormal smooth muscle cell growth in lymphangioleiomyomatosis (LAM): role for tumor suppressor TSC2. Am J Respir Cell Mol Biol 2006; 34: 561-572.
100. Juvet SC, McCormack FX, Kwiatkowski DJ, et al. Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans. Am J Respir Cell Mol Biol 2006; 38: 398-408.
101. Taveira-DaSilva AM, Moss J. Lymphangioleiomyomatosis. Cancer Control 2006; 13: 276-285.
102. Krymskaya VP. Smooth muscle-like cells in pulmonary lymph- angioleiomyomatosis. Proc Am Thorac Soc 2008; 5: 119-126.
103. Yu J, Parkhytko AA, Henske EP. Mammalian target of rapamycin signaling and autophagy. Roles in lymphangioleio- myomatosis therapy. Proc Am Thorac Soc 2010; 7: 48-53.
104. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangio- leiomyomatosis. N Engl J Med 2008; 358: 140-151.
105. Davies DM, Johnson SR, Tattersfield AE, et al. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med 2008; 358: 200-203.
106. Moses MA, Harper J, Folkman J. Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Eng J Med 2006; 354: 2621-2622.
107. Johnson SR, Cordier JF, Lazor R, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. ERS Task Force. Eur Respir J 2010; 35: 14-26.
108. Nurok M, Eslick I, Carvalho CR, et al. The international LAM registry: a component of an innovative web-based clinician, researcher, and patient-driven rare disease research platform. Limphat Res Biol 2010; 8: 81-87.
109. Cassandro R, Harari S. Pulmonary arterial hypertension second- ary to chronic lung diseases: pathogenesis and medical treatment. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23: 163-179.
110. Behr J, Ryu JH. Pulmonary hypertension in interstitial lung disease. Eur Respir J 2008; 31: 1357-1367.
111. Nathan SD. Pulmonary hypertension in interstitial lung disease. Int J Clin Pract Suppl 2008; 160: 21-28.
112. Nathan SD, Shlobin OA, Ahmad S, et al. Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration 2008; 76: 288-294.
113. Hamada K, Nagai S, Tanaka S, et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prog- nosticator in patients with idiopathic pulmonary fibrosis. Chest 2007; 131: 650-657.
114. Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129: 746-752.
115. Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005; 128: 2393-2399.
116. Allanore Y, Borderie D, Avouac J, et al. High N-terminal pro- brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008; 58: 284-291.
117. Leuchte HH, Neurohr C, Baumgartner R, et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2004; 170: 360-365.
118. Whelan TP, Dunitz JM, Kelly RF, et al. Effect of preoperative pulmonary artery pressure on early survival after lung trans- plantation for idiopathic pulmonary fibrosis. J Heart Lung Transplant 2005; 24: 1269-1274.
119. Fell CD, Martinez FJ. The impact of pulmonary arterial hypertension on idiopathic pulmonary fibrosis. Chest 2007; 131: 641-643.
120. Nathan SD, Shlobin OA, Ahmad S, et al. Pulmonary hyperten- sion and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 2007; 131: 657-663.
121. Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema: a distinct under-recognised entity. Eur Respir J 2005; 26: 586-593.
122. Cottin V, Fabien N, Khouatra C, et al. Anti-elastin autoantibodies are not present in combined pulmonary fibrosis and emphy- sema. Eur Respir J 2009; 33: 219-221.
123. Cottin V, Le Pavec J, Prévot G, et al. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 2010; 35: 105-111.
124. Mejia M, Carrillo G, Rojas-Serrano J, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 2009; 136: 10-15.